Entropy Neurodynamics

Entropy Neurodynamics Days Payable Outstanding

The Days Payable Outstanding (DPO) of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 2,892.40. In the previous year, Days Payable Outstanding (DPO) was 1,481.57 — a change of 95.22% (higher).

Days Payable Outstanding

2,892.40

YoY

95.22%

Last updated:

Days Payable Outstanding (DPO) of Entropy Neurodynamics is 2026 2,892.40 . Days Payable Outstanding (DPO) of Entropy Neurodynamics was 2025 1,481.57 . It decreases by 95.22% higher compared to the previous year.

The Entropy Neurodynamics Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
44,709.68 AUD
Jan 1, 2019
222.18 AUD
Jan 1, 2020
131.35 AUD
Jan 1, 2021
111.14 AUD
Jan 1, 2024
68,415.21 AUD
Jan 1, 2025
1,481.57 AUD
Jan 1, 2026
2,892.40 AUD
The Entropy Neurodynamics Days Payable Outstanding history
YEARDays Payable OutstandingYoY
2,892.40+95.22%
1,481.57-97.83%
68,415.21+61,457.74%
111.14-15.38%
131.35-40.88%
222.18-99.50%
44,709.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Days Payable Outstanding (DPO) of Entropy Neurodynamics is 2,892.40 in 2026.

Days Payable Outstanding (DPO) of Entropy Neurodynamics changed from 1,481.57 to 2,892.40, representing a 95.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Entropy Neurodynamics with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics